TVRD — Tvardi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1346830 ·
Last close
$2.10
Market Cap
$19.70M
52W High
$5.69
52W Low
$1.50
ADV30
4,740,960
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -7,051,000 | -6,804,000 | 25,817,000 | 19,851,000 | 11,312,000 |
| Dec 2025 | 0 | — | -7,587,000 | -7,275,000 | 32,073,000 | 20,734,000 | 11,127,000 |
| Sep 2025 | 0 | — | -5,938,000 | -5,527,000 | 39,021,000 | 21,418,000 | 11,155,000 |
| Jun 2025 | 0 | — | -8,869,000 | 4,167,000 | 43,750,000 | 1,048,000 | 10,823,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-23,499,000
Investing CF
$-10,084,000
Financing CF
$22,703,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-110,450,000
Inventory
$900,000
Receivables
$2,238,000
ST Investments
$10,077,000
EBIT TTM
$-24,433,000
Pretax Income TTM
$-13,541,000
Interest Exp TTM
$2,867,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,748,000 | -18,214,000 | 32,073,000 | 11,127,000 | — | -23,499,000 |
| Dec 2024 | 0 | -28,107,000 | -29,397,000 | 35,199,000 | 126,330,000 | — | -18,305,000 |
| Dec 2023 | 0 | -18,665,000 | -17,347,000 | 27,001,000 | 89,059,000 | — | -21,040,000 |
| Dec 2022 | 0 | -21,193,000 | -20,542,000 | 45,097,000 | 90,148,000 | — | -17,866,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SKYE | Skye Bioscience, Inc. | $20.00M | $0.57 | — |
| ALLR | Allarity Therapeutics, Inc. | $19.25M | $1.21 | — |
| CLRB | Cellectar Biosciences, Inc. | $20.54M | $2.57 | — |
| MRKR | Marker Therapeutics, Inc. | $18.84M | $1.13 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $20.65M | $2.07 | — |
News headlines (Yahoo Finance, 1h cache)
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
2026-07-30 11:30 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Events
2026-05-21 12:00 · Yahoo
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-05-08 11:00 · Yahoo
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-04-02 12:00 · Yahoo
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-03-31 20:01 · Yahoo
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
2026-07-07 11:00 · Yahoo
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
2026-07-09 14:52 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Conferences
2026-02-12 13:00 · Yahoo
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
2026-02-07 13:48 · Yahoo
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
2026-01-08 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.